Comparative analysis of the angiotensin receptors blockers and angiotensin-converting enzyme inhibitors in the treatment of arterial hypertension (review of literature)
Cardiovascular diseases are still one of the main causes of death and disability among the adult population, the search for optimal pharmacotherapy of arterial hypertension remains an urgent task. The renin-angiotensin-aldosterone system (RAAS) plays a direct role in the pathophysiology of arterial hypertension, being responsible for regulating fluid volume and maintaining water - salt balance. RAAS is also responsible for the processes of tissue growth and differentiation, apoptosis, and affects the synthesis of many neurohumoral factors. By increasing the activity of the RAAS angiotensin II contributes to vasoconstriction, increased secretion of aldosterone and the activity of the sympathetic nervous system, which in turn leads to the development and progression of hypertension. Angiotensin–II receptor blockers (ARBs) block the AT1 subtype receptors of the same name, which is accompanied by vasodilation, a decrease in the secretion of vasopressin and aldosterone. RAAS blockade is an effective modern reliable way to control blood pressure, as well as prevent related complications. angiotensin converting enzyme inhibitors and angiotensin receptor blockers have similar hypotensive effects and a high safety profile. Due to differences in the mechanism of action, when taking angiotensin receptor blockers, the frequency of undesirable side effects is recorded less, and, accordingly, adherence to treatment is greater. One of the modern angiotensin receptor blockers, olmesartan in various studies has demonstrated its superiority over angiotensin-converting enzyme inhibitors (ramipril and perindopril) in the treatment of arterial hypertension. Olmesartan has proven itself both in monotherapy and in combination with a dihydropyridine calcium channel blocker or a thiazide diuretic.
Matveenko M.S. 2020. Comparative analysis of the angiotensin receptors blockers and angiotensin-converting enzyme inhibitors in the treatment of arterial hypertension (review of literature). Challenges in Modern Medicine, 43 (4): 490–497 (in Russian). DOI: 10.18413/2687-0940-2020-43-4-490-497
While nobody left any comments to this publication.
You can be first.
Bunova S.S., Zhernakova N.I., Fedorin M.M., Skirdenko Ju.P., Osipova O.A. 2020. Jeffektivnaja antigipertenzivnaja terapija: fokus na upravlenie priverzhennost'ju [Effective antihypertensive therapy: focus on commitment management]. Kardiovaskuljarnaja terapija i profilaktika. 19 (5): 259–266.
Vasil'eva L.V., Gosteva E.V., Popov S.Ju., Tolstyh E.M., Latysheva M.N. 2019. Vlijanie blokady receptorov angiotenzina na kognitivnye pokazateli u bol'nyh arterial'noj gipertenziej s metabolicheskim sindromom [Effect of angiotensin receptor blockade on cognitive indicators in patients with arterial hypertension with metabolic syndrome]. Nauchnye vedomosti Belgorodskogo gosudarstvennogo universiteta. Serija: Medicina. Farmacija. 42 (4): 442–450.
Osipova O.A., Sujazova S.B., Vlasenko M.A., Godlevskaja O.M. 2012. Sravnitel'nyj analiz pokazatelej monitorirovanija sutochnogo arterial'nogo davlenija u bol'nyh arterial'noj gipertenziej i hronicheskoj serdechnoj nedostatochnost'ju [Comparative analysis of daily blood pressure monitoring indicators in patients with arterial hypertension and chronic heart failure]. Fundamental'nye issledovanija. 7 (1). C. 146–150.
Bangalore S., Fakheri R., Toklu B., Ogedegbe G., Weintraub H., Messerli F.H. 2016. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? Insights from 254,301 patients from randomized trials. Mayo. Clin. Proc. 91: 51–60. doi: 10.1016/j.mayocp.2015.10.019.
Burbure N., Lebwohl B., Arguelles-Grande C., Green P.H., Bhagat G., Lagana S. 2016. Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology. Hum. Pathol. 50: 127–134. doi: 10.1016/j.humpath. 2015.12.001.
Choi E.Y., McKenna B.J. 2015. Olmesartan-associated enteropathy: a review of clinical and histologic findings. Arch. Pathol. Lab. Med. 139: 1242–1247. doi: 10.5858/arpa.2015-0204-RA.
De Bortoli N., Ripellino C., Cataldo N., Marchi S. 2017. Unspecified intestinal malabsorption in patients treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers: a retrospective analysis in primary care settings. Expert Opin Drug Saf. 16: 1221–1225. doi: 10.1080/14740338.2017.1376647.
Ettehad D., Emdin C.A., Kiran A., Anderson S., Callender T., Emberson J., Chalmers J., Rodgers A. and Rahimi K. 2016. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 387: 957–967. doi: 10.1016/S0140-6736(15)01225-8.
Katsanos A.H., Filippatou A., Manios E., Deftereos S., Parissis J., Frogoudaki A., Vrettou A-R., Ikonomidis I., Pikilidou M., Kargiotis O., Voumvourakis K., Alexandrov A.W., Alexan- drov A.V., Tsivgoulis G. 2017. Blood pressure reduction and secondary stroke prevention: a systematic review and metaregression analysis of randomized clinical trials. Hypertension. 69: 171–179. doi:10.1161/Hypertensionaha.116.08485.
Li Z., Li Y., Liu Y., Xu W., Wang Q. 2017. Comparative risk of new-onset diabetes mellitus for antihypertensive drugs: a network meta-analysis. J. Clin. Hypertens. (Greenwich); 19: 1348–1356. doi: 10.1111/jch.13108.
Malfertheiner P., Ripellino C., Cataldo N. 2018. Severe intestinal malabsorption associated with ACE inhibitor or angiotensin receptor blocker treatment. An observational cohort study in Germany and Italy. Pharmacoepidemiol. Drug. Saf. 27: 581–86.
Messerli F.H., Bangalore S. 2017. Angiotensin receptor blockers reduce cardiovascular events, including the risk of myocardial infarction. Circulation. 135: 2085–2087. doi: 10.1161/Circulationaha.116.025950.
Potier L., Roussel R., Elbez Y., Marre M., Zeymer U., Christopher M., Ohman M., Eagle K., Bhatt D., Gabriel P. 2017. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk. Heart. 103: 1339–46.
Redon J., Pichler G. Missed Dose Study Group. 2016. Comparative study of the efficacy of olmesartan/amlodipine vs. perindopril/amlodipine in peripheral blood pressure after missed dose in type 2 diabetes. J. Hypertens. 34: 359–67.
Redon J., Pichler G. Missed Dose Study Group. 2016. Comparative study of the efficacy of olmesartan/amlodipine vs. perindopril/amlodipine in peripheral and central blood pressure parameters after missed dose in type 2 diabetes. Am. J. Hypertens. 29: 1055–62.
Ruilope L.M. 2016. Sevitension Study Investigators Fixed-combination olmesartan/amlodipine was superior to perindopril + amlodipine in reducing central systolic blood pressure in hypertensive patients with diabetes. J. Clin. Hypertens. (Greenwich) 18: 528–535. doi: 10.1111/jch.12673.
Wang B., Wang F., Zhang Y. 2015. Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 3: 263–274. doi: 10.1016/S2213-8587(14)70256-6.
Williams Bryan, Giuseppe Mancia, Wilko Spiering, Enrico Agabiti Rosei, Michel Azizi, Michel Burnier, Denis L. Clement, Antonio Coca, Giovanni de Simone, Anna Dominiczak, Thomas Kahan, Felix Mahfoud, Josep Redon, Luis Ruilope, Alberto Zanchetti, Mary Kerins, Sverre E. Kjeldsen, Reinhold Kreutz, Stephane Laurent, Gregory Y.H. Lip, Richard McManus, Krzysztof Narkiewicz, Frank Ruschitzka, Roland E. Schmieder, Evgeny Shlyakhto, Costas Tsioufis, Victor Aboyans, Ileana Desormais, Williams B., Mancia G., Spiering W. 2018. ESC/ESH Guidelines for the management of arterial hypertension. Eur. Heart. J. 39 (33): 3021–104.
Whelton P.K., Carey R.M., Aronow W.S., Casey Jr. D.E., Collins K.J. 2018. ACC/AHA/AAPA/ABC /ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 71: e13–e115.
Zanelli M., Negro A., Santi R., Bisagni R., Ragazzi A., Ascani M., S & De Marco. 2017. Letter: sprue-like enteropathy associated with angiotensin II receptor blockers other than olmesartan. Aliment. Pharmacol. Ther. 46: 471–473. doi: 10.1111/apt.14176.
Zhao D., Wang Z.M., Wang L.S. 2015. Prevention of atrial fibrillation with reninangiotensin system inhibitors in patients with hypertension: a meta-analysis of randomized controlled trials. j. biomed. Res. 29: 475–485.